Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma

• Published in: Cancer research and treatment Vol. 56; no. 3; pp. 920 - 935
• Main Authors: Yoon, Sang Eun, Shin, Seung-Ho, Nam, Dae Keun, Cho, Junhun, Kim, Won Seog, Kim, Seok Jin
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Cancer Association 01.07.2024; 대한암학회
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Feasibility Studies; Female; Humans; Lymphoma, Follicular - blood; Lymphoma, Follicular - diagnosis; Lymphoma, Follicular - drug therapy; Lymphoma, Follicular - genetics; Lymphoma, Follicular - mortality; Male; Middle Aged; Mutation; Original; Prognosis; Rituximab - therapeutic use; Treatment Outcome; 의학일반; Follicular lymphoma; Mutations; Prognosis; Circulating tumor DNA
• ISSN: 1598-2998; 2005-9256; 2005-9256
• DOI: 10.4143/crt.2023.869

Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.Results Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.Conclusion Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.